Peter J Felock
Overview
Explore the profile of Peter J Felock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bungard C, Williams P, Ballard J, Bennett D, Beaulieu C, Bahnck-Teets C, et al.
ACS Med Chem Lett
. 2016 Jul;
7(7):702-7.
PMID: 27437081
A novel HIV protease inhibitor was designed using a morpholine core as the aspartate binding group. Analysis of the crystal structure of the initial lead bound to HIV protease enabled...
2.
Lu M, Felock P, Munshi V, Hrin R, Wang Y, Yan Y, et al.
Antimicrob Agents Chemother
. 2012 Mar;
56(6):3324-35.
PMID: 22391531
MK-6186 is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) which displays subnanomolar potency against wild-type (WT) virus and the two most prevalent NNRTI-resistant RT mutants (K103N and Y181C) in biochemical...
3.
Lai M, Lu M, Felock P, Hrin R, Wang Y, Yan Y, et al.
Antimicrob Agents Chemother
. 2010 Sep;
54(11):4812-24.
PMID: 20805392
Studies were conducted to investigate mutation pathways among subtypes A, B, and C of human immunodeficiency virus type 1 (HIV-1) during resistance selection with nonnucleoside reverse transcriptase inhibitors (NNRTIs) in...
4.
Su D, Lim J, Tinney E, Tucker T, Saggar S, Sisko J, et al.
Bioorg Med Chem Lett
. 2010 Jul;
20(15):4328-32.
PMID: 20609585
Biaryl ethers were recently reported as potent NNRTIs. Herein, we disclose a detailed effort to modify the previously reported compound 1. We have designed and synthesized a series of novel...
5.
De Zotti M, De Borggraeve W, Kaptein B, Broxterman Q, Singh S, Felock P, et al.
Biopolymers
. 2010 Jun;
96(1):49-59.
PMID: 20560143
AIDS is produced by HIV-induced infections. HIV integrase is an important enzyme as it is critical for the integration of the HIV genome into that of the host cell. This...
6.
De Zotti M, DAmato F, Formaggio F, Crisma M, Schievano E, Mammi S, et al.
Chemistry
. 2009 Nov;
16(1):316-27.
PMID: 19937615
Integramide A is a 16-amino acid peptide inhibitor of the enzyme HIV-1 integrase. We have recently reported that the absolute stereochemistries of the dipeptide sequence near the C terminus are...
7.
Su D, Lim J, Tinney E, Wan B, Young M, Anderson K, et al.
J Med Chem
. 2009 Nov;
52(22):7163-9.
PMID: 19883100
Biaryl ethers were recently reported as potent NNRTIs. Herein we disclose a detailed SAR study that led to the biaryl ether 6. This compound possessed excellent potency against WT RT...
8.
Su D, Lim J, Tinney E, Wan B, Young M, Anderson K, et al.
Bioorg Med Chem Lett
. 2009 Jul;
19(17):5119-23.
PMID: 19631528
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are key elements of multidrug regimens, called HAART (Highly Active Antiretroviral Therapy), that are used to treat HIV-1 infections. Elucidation of the structure-activity relationships of...
9.
De Zotti M, Formaggio F, Kaptein B, Broxterman Q, Felock P, Hazuda D, et al.
Chembiochem
. 2008 Oct;
10(1):87-90.
PMID: 18850604
No abstract available.
10.
Tucker T, Sisko J, Tynebor R, Williams T, Felock P, Flynn J, et al.
J Med Chem
. 2008 Oct;
51(20):6503-11.
PMID: 18826204
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been shown to be a key component of highly active antiretroviral therapy (HAART). The use of NNRTIs has become part of standard combination antiviral...